A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma (NCT06115135)

🧪 Interventions in This Study

• Venetoclax (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (2 Sites)

• Berenson Cancer Center — West Hollywood, California
• Nebraska Cancer Specialists — Omaha, Nebraska

📞 Contact the Study Coordinator

Phone: (310) 464-2190

Email: rbailey@oncotherapeutics.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma in Relapse

• Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma — Denver, Colorado
• Impact of a Health Technology Intervention on Patient Activation in Multiple Myeloma — Fayetteville, Arkansas
• Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) — Gilbert, Arizona
• Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma — Aurora, Colorado
• A Trial of Selinexor, Ruxolitinib and Methylprednisolone — West Hollywood, California

Explore by condition: All Multiple Myeloma in Relapse clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.